Lab21 hires cfo

Susan Lowther joins Cambridge, UK-based firm

Lab21, a Cambridge, UK-based specialist in personalised medicine, has hired Susan Lowther as chief financial officer.

Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.

Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’

You may also like

Research & Development

Lab21 sells South Carolina laboratory operations

Will continue to focus on diagnostic content opportunities within the US market
Finance

Lab21 acquires Myconostica

Expands growing proprietary diagnostic portfolio
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Manufacturing

Andelyn Biosciences launches LVV Curator platform, bringing proven viral vector platform pedigree to Lentiviral Vector manufacturing for cell therapies

New platform leverages the established Curator platform methodology to industrialise Lentivirus processes from concept to clinic
Subscribe now